1 / 17

Highlights of MACS and WIHS Protocol and Cohorts

Highlights of MACS and WIHS Protocol and Cohorts. Lisa Jacobson Stephen Gange May 25, 2005 Not for distribution or publication outside the Multicenter AIDS Cohort Study or Women’s Interagency HIV Study. Joe Margolick, Baltimore. John Phair, Chicago. Lisa Jacobson, CAMACS.

gene
Download Presentation

Highlights of MACS and WIHS Protocol and Cohorts

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Highlights of MACS and WIHSProtocol and Cohorts Lisa Jacobson Stephen Gange May 25, 2005 Not for distribution or publication outside the Multicenter AIDS Cohort Study or Women’s Interagency HIV Study

  2. Joe Margolick, Baltimore John Phair, Chicago Lisa Jacobson, CAMACS MACSPrincipal Investigators and Sites Roger Detels, Los Angeles Charles Rinaldo, Pittsburgh November 2004

  3. WIHSPrincipal Investigators and Sites Kathryn Anastos, Bronx Alexandria Levine, Los Angeles Mardge Cohen, Chicago Howard Minkoff, Brooklyn Stephen Gange, WDMAC Mary Young, District of Columbia Ruth Greenblatt, San Francisco November 2004

  4. Passwordprotected May 2005

  5. MACS Working Groups - Chairs • Behavioral - D. Ostrow • Clinical - F. Palella • Core Laboratory - C. Rinaldo & J. Margolick • Data - L. Jacobson • Malignancy/Pathology - O. Martinez-Maza • Metabolic/Cardiovascular - L. Kingsley • Neuropsychology - E. Miller • Viral Hepatitis - C. Thio November 2004

  6. WIHS Scientific Working Groups - Chairs • Aging/Neurocognitive – M. Young • Behavior/Drug Use – T. Wilson / D. Vlahov • Cancer/Pathology – N. Hessol • Cardiovascular – R. Kaplan • Epidemiology – A. French • GYN – H. Minkoff • Hepatitis – M. Peters • HIV Virology - B. Weiser • HPV – H. Strickler • Immunology - L. Al-Harthi • Laboratory/Specimen – W. Meyer • Metabolic – P. Tien • Pharmacology - R. Greenblatt • Statistical/Analytical – A. Kalinowski May 2005

  7. MACS / WIHS Cohort: Summary May 2005

  8. Semiannual Visit • Medications • Antivirals, OI-specific, adherence • Physical Examination / GYN (WIHS) • Anthropomorphic/ lipodystrophy measures • Hand grip / timed walk (MACS v43.5; WIHS v22) • Questionnaire / ACASI (MACS) • Medical History, Health Services, Behavior • Demographics / Psychosocial • Quality of Life • Neuropsychological Screening • Specimens and Labs • Plasma, Serum, Cells, CVL (WIHS), Hair (WIHS HIV+) • T-cells, HIV RNA, HBV & HCV serology, lipids • B-cell lines, National Repository May 2005

  9. Continuous Outcome Ascertainment • Seroconversion • Clinical Outcomes (medical record confirmation) • AIDS diagnoses • Non-AIDS diagnoses • Cardiovascular disease • Cerebrovascular disease • Kidney disease (MACS) • Liver disease • Lung infection, bacterima, septicemia (MACS), TB (WIHS) • Malignancies • Neurologic • Mortality and cause of death November 2004

  10. Descriptive Statistics May 2005

  11. MACS/WIHS Database *Available as of 5/9/2005 May 2005

  12. Demographics of MACS/WIHS Cohorts: Baseline November 2004

  13. HIV Disease Markers at Most Recent Visit:Current MACS/WIHS Cohorts November 2004

  14. Antiretroviral Therapy Use Among Seropositives NRTI Monotherapy NRTI Combination Therapy HAART with PI HAART no PI 100 MACS WIHS 80 60 40 20 0 1995 1997 1999 2001 2003 1995 1997 1999 2001 2003 Calendar Time May 2005

  15. Age Distribution among Active HIV+ MACS & WIHS Participants May 2005

  16. Age Distribution among Active HIV- MACS & WIHS Participants May 2005

  17. HAART Use in the MACS/WIHS Cohorts MACS Cumulative Incidence MACS Incidence Rate 100 WIHS Cumulative Incidence WIHS Incidence Rate 80 60 Incidence of HAART per 100 P-SEM 40 20 0 96-1 97-1 98-1 99-1 00-1 01-1 02-1 03-1 04-1 Calendar (Year-Semester) May 2005

More Related